Icahn

© Reuters. FILE PHOTO: A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake (Reuters) -Illumina Chief Executive Officer Francis DeSouza…

Illumina chief executive Francis deSouza has resigned following a bruising proxy battle with activist investor Carl Icahn over the future of the world’s biggest gene sequencing company.Illumina said on Sunday that the company’s board…

Decades ago, Carl Icahn gained a formative insight from reading the American novelist Theodore Dreiser. The billionaire investor was absorbed by two of Dreiser’s novels, The Financier and The Titan, which chronicle the rise of…

Rafael Henrique | Lightrocket | Getty ImagesActivist investor Carl Icahn on Thursday won enough support from Illumina shareholders to oust the biotech company's board chair.Shareholders booted chairman John Thompson. An Illumina…

US short seller Hindenburg Research has unveiled a position against Icahn Enterprises, the publicly listed fund run by activist Carl Icahn, knocking its share price and setting up a battle between two of Wall Street’s most feared and…

Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan | CNBCCarl Icahn on Friday called Illumina's first-quarter results "very disappointing" and slammed the DNA sequencing company's new plans to cut costs. …

Carl Icahn, chairman of Icahn Enterprises HoldingsScott Eelis | Bloomberg | Getty ImagesCarl Icahn on Wednesday said Illumina's efforts to appeal a Federal Trade Commission order to divest the highly contested Grail acquisition "is an…

Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan | CNBCCarl Icahn blasted Illumina for nearly doubling its CEO's pay last year despite a dramatic drop in the biotech company's market value since closing…

Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan | CNBCCarl Icahn on Wednesday said Illumina should bring back its former CEO "immediately," his latest move in a brewing proxy fight with the biotech…

Carl Icahn on Friday alleged that Illumina's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer test developer Grail in 2021. The claim is the latest…